Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: August 11, 2025
Reporting Period: Second Quarter ended June 30, 2025
Business Overview: The Company is a Delaware corporation focused on therapeutic development, with principal executive offices in San Diego, California. This filing announces the release of financial results for the quarter ended June 30, 2025.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) containing the detailed financial data. The text of this filing does not provide specific values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Investors must refer to the attached Exhibit 99.1 (Press Release) for these figures.
Material Changes
The filing text does not contain specific data regarding material changes in financial performance or operational metrics compared to the prior comparable period. Such details are contained within the referenced press release.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that the Company issued a press release titled "Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update." This suggests the inclusion of a corporate update, but the specific content regarding guidance, outlook, or risks is not detailed in the 8-K text itself.
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, net loss, and cash burn figures.
- Verify the "Corporate Update" section in the press release for any changes in clinical trial timelines or regulatory milestones.
- Confirm current cash runway and liquidity status as of June 30, 2025, which are not listed in this summary document.
- Check for any new risk factors or contingencies disclosed in the full press release text.